Rearrangements of the anaplastic lymphoma kinase (ALK) gene account for 5-6% in non-small cell lung cancer (NSCLC). ALK rearranged NSCLC is sensitive to ALK tyrosine kinase inhibitors (TKIs) but prone to drug resistance. Meanwhile, ALK rearranged NSCLC has poor response to single immunotherapy. Here we mainly describe the immune escape mechanisms of ALK mutated NSCLC and the role of related biomarkers. Additionally, we collate and evaluate preclinical and clinical studies of novel immune combination regimens, and describe the prospects and perspectives for the application of novel immune technologies in patients with ALK rearranged NSCLC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795041 | PMC |
| http://dx.doi.org/10.3389/fonc.2022.1016869 | DOI Listing |
Publication Analysis
Top Keywords
alk rearranged
16
rearranged nsclc
16
novel immune
8
alk
7
nsclc
6
current status
4
status challenges
4
challenges immunotherapy
4
immunotherapy alk
4
rearranged
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!